Literature DB >> 12377192

Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter.

Rénald Gilbert1, An Liu, Basil Petrof, Josephine Nalbantoglu, George Karpati.   

Abstract

Dystrophin gene transfer using gutted or helper-dependent adenoviruses (HDAd), which have most of their genes deleted, is a promising approach to treat Duchenne muscular dystrophy. In an attempt to boost the amount of dystrophin produced after gene transfer, we have constructed a fully deleted HDAd (HDCBDys2x) containing two human dystrophin cDNAs controlled by the powerful hybrid cytomegalovirus enhancer/beta-actin promoter. We demonstrated high dystrophin expression after infection of muscle cultures with HDCBDys2x. Similarly, high (mean=583) and moderate (mean=124) numbers of muscle fibers were transduced in anterior tibialis muscle after intramuscular injection of HDCBDys2x in neonate and adult dystrophindeficient (mdx) mice 10 days postinjection. In fact, in the neonatally injected mdx mice, the transferred dystrophin was five times more abundant than in normal human muscle. However, the high early transduction level was transient in both animal groups, and we observed a humoral response against the human dystrophin. In contrast, we demonstrated sustained dystrophin expression in immunodeficient mouse muscles. Dystrophin expression of HDCBDys2x could be further increased in the presence of an E1/E3-deleted (first-generation) adenovirus, thus demonstrating that the latter vector synthesizes trans-acting enhancing factors. We have achieved abundant dystrophin expression with our new, improved HDAd. It is anticipated that high longterm transgene expression will be possible by employing weaker immunogenic transgenes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377192     DOI: 10.1006/mthe.2002.0689

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  4 in total

1.  Pancreatic transduction by helper-dependent adenoviral vectors via intraductal delivery.

Authors:  Meritxell Morró; Joan Teichenne; Veronica Jimenez; Ramona Kratzer; Serena Marletta; Luca Maggioni; Cristina Mallol; Jesus Ruberte; Stefan Kochanek; Fatima Bosch; Eduard Ayuso
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

2.  Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability.

Authors:  Manuel A F V Gonçalves; Gijsbert P van Nierop; Marloes R Tijssen; Pierre Lefesvre; Shoshan Knaän-Shanzer; Ietje van der Velde; Dirk W van Bekkum; Dinko Valerio; Antoine A F de Vries
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 3.  Hutchinson-Gilford Progeria Syndrome-Current Status and Prospects for Gene Therapy Treatment.

Authors:  Katarzyna Piekarowicz; Magdalena Machowska; Volha Dzianisava; Ryszard Rzepecki
Journal:  Cells       Date:  2019-01-25       Impact factor: 6.600

4.  MAR-mediated integration of plasmid vectors for in vivo gene transfer and regulation.

Authors:  Stefania Puttini; Ruthger W van Zwieten; Damien Saugy; Małgorzata Lekka; Florence Hogger; Deborah Ley; Andrzej J Kulik; Nicolas Mermod
Journal:  BMC Mol Biol       Date:  2013-12-02       Impact factor: 2.946

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.